Denosumab as the Treatment of Recalcitrant Tuberculous Pleural Effusion-Associated Hypercalcemia
Denosumab is a human monoclonal antibody that binds to RANKL (receptor activator of nuclear factor-kappa B ligand). It has mainly been used in the treatment of osteoporosis for a variety of causes especially in situations refractory to bisphosphonates or when kidney function is impaired. It is also...
Main Authors: | Abd Jalil, A.A (Author), Abdul Rani, M.F (Author), Mohamad, A.F (Author), Wan Muhamad Hatta, S.F (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021
|
Series: | Case Reports in Medicine
|
Subjects: | |
Online Access: | View Fulltext in Publisher View in Scopus |
Similar Items
-
Denosumab for management of severe hypercalcemia in primary hyperparathyroidism
by: Anna Eremkina, et al.
Published: (2020-10-01) -
Denosumab for Breast Cancer with Bone Metastases-Induced Hypercalcemia Complicated with Acute Renal Failure
by: Chen-Yu Kuo, et al.
Published: (2015-06-01) -
Denosumab Use in a Patient with Bisphosphonate-Resistant Humoral Hypercalcemia of Malignancy
by: Maali M. Milhem, et al.
Published: (2016-01-01) -
Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report
by: Yves Maugars, et al.
Published: (2020-08-01) -
Pamidronate Rescue Therapy for Hypercalcemia in a Child With Williams Syndrome
by: Sami A. Sanjad, et al.
Published: (2018-05-01)